Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28868247 | 0.91 | ESR1 (0.51) | HTTCASP3CASP7CASP9CYP3A4 | |
| SCHEMBL2007903 | 0.90 | PDE5A (0.53) | HTTCASP3CASP7CASP9CYP3A4 | |
| SCHEMBL2007639 | 0.88 | GAA (0.49) | HTTCASP3CASP7CASP9TSHR | |
| SCHEMBL2007664 | 0.86 | CASP3 (0.46) | HTTCASP3CASP7CASP9CYP3A4 | |
| SCHEMBL2010455 | 0.84 | HMGCR (0.53) | HTTCASP3CASP7CASP9TSHR | |
| SCHEMBL2010341 | 0.84 | HMGCR (0.53) | HTTCASP3CASP7CASP9HMGCR | |
| SCHEMBL29184842 | 0.80 | CYP3A4 (0.58) | HTTCASP3CASP7CASP9CYP3A4 | |
| SCHEMBL2010997 | 0.79 | HPGD (0.70) | CYP3A4HPGDALDH1A1 | |
| SCHEMBL10545845 | 0.79 | HPGD (0.52) | CASP3CASP7CASP9CYP3A4TSHR | |
| SCHEMBL2012737 | 0.79 | HPGD (0.59) | CYP3A4HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | HTT 1966/4885CASP3 4105/4885CASP7 4127/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | HTT 1966/4885CASP3 4105/4885CASP7 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.